NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Gary, take AMRN as an example.

They are looking at a decision almost exactly one year after results.

Now, this is a case where the drug is already approved. So a lot of the meat in the process has already been completed. Investors may ignore all those details, but they are very real. A hell of a lot more work than a SAP modification.

Plus AMRN already had experience in the process. And they had resources.

SO 1 year from top line is aggressive, and likely 18 months would be a better target.

And how soon to top line? Who knows.